PMH48 A Review of Clinical outcome Assessments used in FDA approved Drug labels for Mental Health conditions  by Pompilus, F.A. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A123
displaying seven treatment attributes: medication, therapy, school involvement, 
caregiver behavior training, physician management, provider communication 
and out-of-pocket costs. Every attribute was operationalized into 3 possible levels. 
Within each task, caregivers selected one best and one worst attribute. A scale-
adjusted latent-class (SALC) analysis was conducted to account for variability in the 
consistency of responses. RESULTS: Our study population of 164 caregivers were 
on average 42 years old (SD 8.7), predominantly female (95%), white (65%), married 
(61%), college-educated (73%), and 20% had a child who was diagnosed with ADHD 
for ≤ 1year. Based on the aggregate results, using medication everyday was the most 
preferred treatment attribute (coefficient= 2.41, p< 0.001). Three latent classes (i.e. 
segments) that best described the data were identified, and the scale factor included 
in the model was significant (p< 0.001). The 3 segments comprised 28%, 27%, and 45% 
of our study population. Segment 1 has the strongest preference for ‘medication’ 
(coefficients= 3.69 –4.34, all p< 0.001) while Segment 2 displayed the least preference 
for medication (coefficients= -1.49 – -3.36, all p< 0.001). Segment 3 was most cost-
avoidant (coefficients= -2.13 – -6.11, all p< 0.001) but had the strongest preference 
for ‘school involvement’ (coefficients= 0.63 – 2.58, all p< 0.05). CONCLUSIONS: This 
study demonstrated variation in caregivers’ priorities for ADHD treatment attrib-
utes. A better understanding of preferences for evidence-based treatment options 
can enhance patient-centered care. By utilizing SALC, our study reduces the likeli-
hood of misclassification error.
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OBJECTIVES: Patient focus groups were conducted to identify the most important 
clinical attributes and outcomes of pharmacological treatments for bipolar depres-
sion influencing patients’ treatment adherence decisions. Qualitative results will 
guide the development of a quantitative discrete choice experiment to determine 
patient preferences and willingness to trade-off between medication character-
istics. METHODS: Adults clinically diagnosed with bipolar I disorder, recently 
depressed, previously/currently treated with antipsychotics, and not currently 
suicidal were recruited from two clinical sites. Following an IRB-approved (E&I 
Review Services) protocol, inclusion criteria, and semi-structured, open-ended 
discussion guide, focus groups lasting 90-minutes were conducted to discuss 
patients’ expectations and experiences towards treatment safety and efficacy. 
Focus groups recordings were transcribed, a data coding dictionary developed, 
and ATLAS.ti used for qualitative data analysis. RESULTS: From the two focus 
groups conducted (n= 8 each; Total N= 16; mean age 47.9±6.4 years; 68.8% female, 
mean time since diagnosis 15.7±11.4 years; mean length of atypical antipsychotic 
use 4.7±4.6 years), participants were most concerned with treatment efficacy, 
expecting a medication to balance the “highs and lows” of bipolar symptoms and 
providing “clarity” (control of thoughts and actions). One in 4 expected symptom 
improvements within 2-3 weeks of treatment initiation, and would tolerate side 
effects and less desirable features, as long as these did not outweigh treatment 
benefits. Side effects mentioned spontaneously and rated most highly by partici-
pants as influencing treatment initiation and persistence decisions were weight 
gain (n= 8, 50.0%) and sedation/fatigue (n= 7, 43.8%). To manage side effects, most 
(n= 7, 43.8%) reported self-treatment by reducing dosage or discontinuing without 
medical consultation. CONCLUSIONS: Treatment efficacy, faster onset in terms of 
symptom improvement, less weight gain, and less severe sedation/fatigue were 
identified as most important outcomes determining patients’ treatment decisions. 
Based on qualitative results, identified treatment attributes will be included in 
a quantitative discrete choice experiment to determine patients’ preferences for 
bipolar depression pharmacological treatments.
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OBJECTIVES: Vortioxetine, a novel antidepressant exhibiting a multimodal mecha-
nism of action, was approved for the treatment of adults with major depressive 
disorder (MDD). This extension study of a recently published meta-analysis (Llorca 
et al. Curr Med Res Opin 2014;30(12):2589-606) compares the efficacy and toler-
ability of vortioxetine with seven commonly used antidepressants marketed in 
the US. METHODS: Indirect comparisons using meta-regression, an extension of 
random-effects meta-analysis, were performed using data from 54 double-blind, 
placebo-controlled Phase 3 pivotal studies identified in a systematic review (N= 
18,312 patients). To ensure study comparability, only experimental drug and pla-
cebo arms were included in primary analyses. Study-level standardized effect sizes 
were regressed on active treatment to compare efficacy and tolerability of vorti-
oxetine with branded (levomilnacipran, vilazodone, desvenlafaxine) and generic 
(duloxetine, escitalopram, sertraline, venlafaxine) antidepressants. Efficacy was 
defined as change from baseline on the Montgomery-Asberg Depression Scale 
or Hamilton Depression Rating Scale after 2 months (6-12 weeks) of treatment. 
Tolerability was defined as the withdrawal rate due to any adverse event. RESULTS: 
Standardized mean differences for vortioxetine compared with the selected anti-
depressants (negative estimates favor vortioxetine) were: duloxetine, 0.10 (95% 
confidence interval [CI]: -0.12, 0.32); escitalopram, -0.04 (95% CI: -0.32, 0.24); ser-
traline, -0.02 (95% CI: -0.39, 0.34); venlafaxine, 0.14 (95% CI: -0.11, 0.39); levom-
ilnacipran, -0.05 (95% CI: -0.28, 0.19); vilazodone, -0.23 (95% CI: -0.53, 0.06); and 
desvenlafaxine, 0.04 (95% CI: -0.16, 0.23). Significantly lower withdrawal rates were 
observed for vortioxetine versus sertraline, venlafaxine, and desvenlafaxine (all 
P< 0.05). No statistically significant difference in withdrawal rates was observed 
between vortioxetine and duloxetine, escitalopram, levomilnacipran, or vilazo-
done. CONCLUSIONS: These findings show that vortioxetine offers a comparable 
combination of efficacy and tolerability in MDD to other antidepressants marketed 
in the US.
PMH48
a review of clinical outcoMe assessMents used in fda aPProved 
drug laBels for Mental HealtH conditions
Pompilus F.A.1, Lindberg-Springs S.1, Seoane-Vazquez E.2
1Massachusetts College of Pharmacy & Health Sciences, Boston, MA, USA, 2MCPHS University, 
Boston, MA, USA
OBJECTIVES: Clinical outcome assessments (COAs) are clinician-reported out-
comes (ClinROs), patient-reported outcomes (PROs), observer-reported outcomes 
(ObsROs), and performance outcomes (PerfROs) tools used to assess the patient’s 
symptom, impact, and overall mental state. PRO measures, specifically developed 
to capture the patients’ perspective without clinician interpretation, are consid-
ered an approved means to support labeling by the Food and Drug Administration 
(FDA). This study aims to identify the extent to which COAs were used to support 
label claims and to identify the prevalence of PRO specific measures in men-
tal health drugs approved by the FDA in the period 2006-2014. METHODS: New 
drugs used to treat mental health conditions approved by the FDA from 2006-2014 
were identified and labels were retrieved from using the Drugs@FDA database. 
The “Indications and Usage” and “Clinical Studies” sections of each label were 
reviewed and relevant indications and concordant COA data was extracted and 
categorized by type using PROQOLID. RESULTS: A total of 20 FDA-approved drugs 
for use in mental health conditions were identified. Of these, 18 labels included 
clinical study data and 14 labels used the results of COAs to support 19 indica-
tions; major depressive disorder (n= 5), schizophrenia and/or schizoaffective dis-
order (n= 5), attention deficit hyperactivity disorder (n= 3), bipolar mania (n= 2), 
insomnia (n= 2), seasonal affective disorder (n= 1), depressive episodes associated 
with bipolar I disorder (n= 1). Clinical studies included 32 COAs used 47 different 
times to support drug/indication labeling; 39 ClinROs, 4 ObsROs, and 4 PerfROs 
(none employed PRO measures). COAs were used to measure primary efficacy 
endpoints (n= 41), to establish safety (n= 2) and to determine study eligibility (n= 7) 
(not mutually exclusive). Thirteen out of 14 labels demonstrated efficacy by using 
a COAs. CONCLUSIONS: All mental health drug labels approved by the FDA since 
2006 utilized clinical outcome assessments to support drug efficacy and labeling, 
however PROs were underutilized.
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OBJECTIVES: This review was designed to synthesize information about the 
impact of major depressive disorder (MDD) on functionality, work performance, 
and potential stigma in the emerging markets of Brazil, China (including Taiwan) 
and Russia. METHODS: Studies indexed in MEDLINE (2004-2014) and abstracts from 
relevant conferences were screened with search terms including “depression/MDD,” 
“productivity/employment,” “functionality,” and “stigma.” RESULTS: Sixteen studies 
were extracted for Brazil, 18 for China and 5 for Russia. There was significant study 
heterogeneity in the study populations and outcome measures in the literature. The 
negative correlation of MDD with functionality and work performance was evident 
across countries. In Brazil, depression increased the risk of unemployment by 39% 
(OR 1.39; 95% CI 1.15-1.67) in one study and was significantly predictive of worse 
hrQoL among subpopulations sampled in other studies (P ≤ .001). Depression was 
associated with decreased work performance (OR 0.91; 95% CI 0.87-0.95) in Chinese 
enterprises. In Taiwan, MDD patients experienced an average 5.8-61 sick-leave days 
annually. Depressed (vs non-depressed) Chinese had a higher risk of impairment 
in activities of daily living (RR 2.20-4.29; 95% CI 1.33-8.86). A Russian study reported 
that depression impacted employment for 31.7% of urban-dwelling adults; 12.2% 
reduced working hours, 17.1% became unemployed and 24.4% took an average 74 
± 54 sick-leave days annually. Stigma caused by cultural and social factors was an 
obstacle to help-seeking, MDD diagnosis and treatment in China and Russia but 
not in Brazil. CONCLUSIONS: MDD is correlated with impaired functionality and 
work performance in Brazil, China and Russia. Stigma specific to national environ-
ment should be addressed to remove barriers to MDD treatment. Future longitu-
dinal inquiry is needed to comprehensively evaluate the consequences of MDD. 
New research investigating the impact of MDD and its treatment on functionality 
and work performance among working adults without comorbidities is needed in 
emerging markets.
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OBJECTIVES: It has been known that depression is associated with significant 
impairments in health-related quality of life (HRQOL). However, few studies have 
evaluated HRQOL dysfunction in both physical and mental health domains. This 
study examined the factors, namely demographic, socio-economic and health-
related factors affecting the physical and mental health domains of HRQOL in 
individuals suffering from depression. METHODS: This retrospective, observa-
tional cross-sectional study used data from the 2011 Medical Expenditure Panel 
